Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F. Seymour, Arnon P. Kater, James D’Rozario et al.|New England Journal of Medicine|2018Cited by 907
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variablesAndrew W. Roberts, John F. Seymour, Shuo Ma et al.|Blood|2019Cited by 175